AUTHORS
Sangwan Sim, PhD, Felix A. Radtke, MD2, Gonzalo Villanueva-Martín, PhD3, David Hoytema, MD, PhD4, GeonHo Bae, PhD5, Roxane Darbousset, PhD6, Brittany Esty, MD7, Melissa Elder, MD, PhD8, Denise Heather Bell-Brunson9, Todd Brusko, PhD10, Prescott Atkinson, MD, PhD11, Joseph Churh, MD12, Caleb Cornaby, PhD13, Maurice O'Gorman, PhD14, Ofer Zimmerman, MD15, Sebastian Boluarte, MD16, Regina Clemens, MD, PhD17, Maria Gutierrez-Arcelus, PhD18, Janet Chou, MD19, Neil Romberg, MD20, Peter Nigrovic, MD21
AFFILIATIONS
1 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
2 MRC Weatherall Institute of Molecular Medicine, Oxford, United Kingdom
3 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
4 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
5 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
6 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
7 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
8 University of Florida, Gainesville, Florida, United States
9 University of Florida, Gainesville, Florida, United States
10 University of Florida, College of Medicine, Gainesville, Florida, United States
11 University of Alabama at Birmingham, Birmingham, Alabama, United States
12 Children's Hospital Los Angeles, Los Angeles, California, United States
13 Children's Hospital Los Angeles, Los Angeles, California, United States
14 Children's Hospital Los Angeles, Los Angeles, California, United States
15 Washington University School of Medicine, Saint Louis, Missouri, United States
16 Washington University School of Medicine, Saint Louis, Missouri, United States
17 Washington University School of Medicine, Saint Louis, Missouri, United States
18 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
19 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
20 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
21 Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
PU.1-mutated agammaglobulinemia (PU.MA) is a human inborn error of immunity caused by haploinsufficiency of the pioneer transcription factor PU.1, resulting in B cell aplasia. Despite immunoglobulin replacement, some PU.MA patients exhibit recurrent sinopulmonary infections and other manifestations of immune dysregulation, such as colitis, implying defects beyond the B cell compartment. We studied 10 PU.MA patients recruited through multiple institutions across the United States. Flow cytometric analysis demonstrated increased circulating immature neutrophils, as well as reduced neutrophil surface CD16 (FCGR3) and increased CD66b. Plasma O-link proteomics from 9 PU.MA patients revealed enrichment of pathways related to myeloid activation, neutrophil degranulation, and NETosis compared with healthy and X-linked agammaglobulinemia controls, suggesting a degranulation-associated activation phenotype.
Consistent with this result, single-cell ATAC sequencing of marrow and blood neutrophils from C57BL/6 mice showed that PU.1 motif accessibility and footprinting increased most strikingly during the preNeu-to-immature transition. Mice with neutrophil-specific heterozygous or homozygous deletion of Spi1 (encoding PU.1) using MRP8-Cre (PU.1fl/+ and PU.1ΔNeu) confirmed this role. PU.1ΔNeu mice accumulated CXCR4+cKit+ preNeus and showed reduced immature and mature neutrophil populations. Surface CD11b expression was also decreased in PU.1fl/+ mice, modeling human PU.MA. TNF/fMLP-induced ROS generation declined in a gene dose-dependent manner, while PMA-induced responses were preserved in PU.1fl/+ neutrophils but impaired in PU.1ΔNeu cells, suggesting preferential disruption of receptor-dependent signaling. In IgG immune-complex arthritis dependent on neutrophil Fc gamma receptors, PU.1ΔNeu mice were fully protected, whereas PU.1fl/+ mice exhibited an intermediate phenotype, confirming impairment of neutrophil effector function in vivo. By CITE-seq of marrow and blood, PU.1ΔNeu neutrophils followed an aberrant developmental trajectory that diverged immediately after the preNeu stage and resulted in selective impairment of effector functions implicated in opsonin-dependent and anti-viral host defense.
Together, these findings identify PU.1 dosage as a critical regulator of neutrophil maturation and acquisition of mature antimicrobial effector programs across species. PU.1 haploinsufficiency produces a clinically relevant neutrophil state characterized by impaired host defense despite enhanced degranulation-associated activation, suggesting a mechanistic explanation for persistent infections and immune dysregulation in PU.MA.
DISCLOSURES
Sangwan Sim, PhD: No relevant conflicts of interest to declare.